Jonathan Miller: Understood. Thanks so much.
Grant Pickering: Thanks Jon.
Operator: Thank you. One moment while we prepare for the next question. The next question is coming from Louise Chen of Cantor. Your line is open.
Louise Chen: Hi. Congratulations on the quarter and thanks for taking my questions here. So, one question we asked me to get is since that you’ve already shared proof-of-concept for VAX-24. And because the market for PCV is getting crowded, why not just move forward with VAX31? And then second question I had for you was on the market opportunities for VAX-A1, PG and GI, what do you think of those? How do you think about potential peak sales versus what you might see for your PCV? And when do you plan to start studying for these opportunities? Will it be within the next several years? Or after you kind of move through the pivotal stuff with your PCV? Thank you.
Grant Pickering: Thanks for the question, Louise. Yeah. I mean, certainly, VAX-31 is going to be — I mean, I’m on record for calling it a category killer. But the reality is VAX-24 has a best-in-class profile in both the adult and infant market, and it is on the fastest track to introduction to the market. And so, it’s our primary focus to deliver that vaccine into the market. We believe that VAX-24 is going to be a tremendous introduction for our carrier-sparing PCVs to the market. And we know that upon widespread use of VAX-24, it’s only going to enhance the rate of circulating disease for these strains over and above those that are in VAX-24. So, we know VAX-31 is going to be important. And we have it moving as fast as it can.
And with what we know today, this is the right strategy for the company. If there was something to change either from a competitive dynamic perspective or from an epidemiology perspective, we would be in a position to revisit that, but we believe this is the right way to maximize value for Vaxcyte. And we think it’s the right thing to do societally as a global health solution. And then as it relates to the pipeline, yeah, we think that what we can do with this cell-free protein synthesis platform is going to continue to pay dividends. VAX-A1 is our broad spectrum Group A Strep vaccine. We’ve all been hearing about increasing rates of the circulation of Group A Strep infections. And like PCVs, Group A Strep afflicts adults and infants. So, this is an important and what could be valuable intervention on both ends of the age spectrum.
So, we’re moving that program forward aggressively. And because of that widespread usage, we do think it has blockbuster potential given the magnitude of morbidity and mortality that it can address. And then as it relates to the other programs, VAX-PG, we’ve nominated the lead candidate that we want to advance to address this therapeutic solution for periodontitis. Likewise, we are very excited about the new VAX-GI program for shigellosis. Just on Friday, the CDC came out with an alert about an alarming rate of antibiotic resistance associated with Shigella. So, we’re moving them forward as fast as we can, but in sync with the value equation with PCV at the lead. But we certainly expect to bring on additional programs coming out of our pipeline going forward.
Louise Chen: Thank you.
Operator: Thank you. One moment while we prepare for the next question. Our next question is coming from Joseph Stringer of Needham. Your line is open.
Joseph Stringer: Hi. Thanks for taking the question. Just given that there’s a competitor 24-valent pneumococcal vaccine program out there in mid stage development, can you explain the relative importance of potentially being first to market? And do you think that your current time lines for VAX-24 Phase 3 data readouts put you in a good position relative to that 24-valent competitor?
